In addition, immunosuppressants such as cyclosporine and cyclophosphamide, CD20 monoclonal antibodies and thrombopoietin receptor agonists have become new drugs in clinical treatment of ITP in recent years.[17] TPO is an important growth factor that regulates the proliferation and differentiation of megakaryocytes and mediates the production of platelets by megakaryocytes. Here, TPO is linked to autoimmune thrombocytopenic purpura.